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First isolation of the pan-azole-resistant Aspergillus fumigatus cyp51A TR46/Y121F/T289A mutant in a UK patient Sir, Antifungal resistance in Aspergillus fumigatus owing to a number of mutations has been reported from many regions of the globe. The cyp51A gene TR46/Y121F/T289A mutation is an emerging mechanism conferring resistance to azole antifungal drugs. It is unclear whether these mutations are acquired from specific ecological niches or are generated by long-term exposure to azoles during suboptimal therapy. Previous surveys of azole resistance in the UK have not found this mutation [1] [2] [3] .
A man in his early forties was admitted to the Adult Burns Centre of University This is of clinical importance because first-line therapy for pulmonary aspergillosis is voriconazole [4] as azole resistance is not acknowledged in treatment-naïve patients.
In addition, previous reports have associated the A. fumigatus cyp51A TR46/Y121F/T289A mutant with invasive disease and therapy failure [5] . The extent of azole resistance due to this or other mutations is in the UK is impossible to estimate as susceptibility testing is not routinely performed for clinical and environmental mould isolates. Nevertheless, it is likely that this case represents a 'tip of the iceberg' and that there is an environmental origin. We advocate the introduction of UK-wide genetic analysis of azole-resistant isolates of A. fumigatus to enable monitoring of environmental transmission.
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